FLUICELL AB (PUBL) Inactive Instrument
Fluicell AB (publ) Share Price Nasdaq Stockholm
Equities
SE0010831321
Biotechnology & Medical Research
| Sales 2022 | 3.25M 301K 23.94M | Sales 2023 | 3.34M 309K 24.58M | Capitalization | 17.2M 1.59M 127M |
|---|---|---|---|---|---|
| Net income 2022 | -21M -1.94M -155M | Net income 2023 | -26M -2.4M -191M | EV / Sales 2022 | 4.2 x |
| Net cash position 2022 | 24.46M 2.26M 180M | Net cash position 2023 | 2.76M 255K 20.35M | EV / Sales 2023 | 4.33 x |
| P/E ratio 2022 |
-1.89
x | P/E ratio 2023 |
-0.62
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 97.97% |
More Fundamentals
* Assessed data
More news
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Carolina Trkulja
CEO | Chief Executive Officer | 40 | - |
| Founder | 44 | 01/01/12 | |
| Director of Finance/CFO | 54 | 30/06/23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jan Orwar
BRD | Director/Board Member | 60 | 31/12/14 |
Daniel T. Chiu
BRD | Director/Board Member | 52 | 31/12/16 |
Stefan Tilk
CHM | Chairman | 59 | 31/12/15 |
Fluicell AB is a Sweden-based company within healthcare industry. It commercializes a product portfolio for processing and studying of individual cells, primarily in the field of drug development. The Companyâs products comprise research tools BioPen and Dynaflow Resolve. Tools enable researchers to study, process and measure drug impact on individual cells. Also, the Company develops bioprinting technology Biopixlar Retina in both two-dimensional (2D) and three-dimensional (3D) options. Biopixlar Retina creates complex tissue-like structures with control over positioning of individual cells.
Calendar
09/05/2024
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| +19.91% | 46.81B | |
| -0.72% | 41.37B | |
| +47.07% | 41.29B | |
| -6.20% | 28.87B | |
| +11.65% | 26.06B | |
| -19.66% | 19.13B | |
| +32.68% | 12.39B | |
| +0.44% | 12.08B | |
| +0.29% | 11.96B |
